Tuesday, July 31, 2012

Reuters: Global Markets: Olympus slides seven percent on possible violations report

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Olympus slides seven percent on possible violations report
Aug 1st 2012, 02:51

  • Tweet
  • Share this
  • Email
  • Print
A man sits near a logo of Japan's Olympus Corp at the company headquarters in Tokyo June 19, 2012. REUTERS/Yuriko Nakao

A man sits near a logo of Japan's Olympus Corp at the company headquarters in Tokyo June 19, 2012.

Credit: Reuters/Yuriko Nakao

TOKYO | Tue Jul 31, 2012 10:51pm EDT

TOKYO (Reuters) - Shares of Olympus Corp (7733.T) fell as much as 7 percent on Wednesday, after a report that the U.S. Department of Justice is looking into possible violations by the scandal-tainted firm in a doctor-training program in Brazil and in marketing operations in the United States.

Bloomberg news agency on Wednesday quoted Chairman Yasuyuki Kimoto as saying in a July 23 interview: "We understand DOJ is trying to gather lots of information on us".

Olympus confirmed the comments made by Kimoto to Bloomberg.

The slide in the share price also comes after Terumo Corp (4543.T) filed a lawsuit against Olympus seeking damages for lost shareholder value, escalating a tussle with the endoscope maker over a tie-up proposal.

Terumo, a medical device maker, which holds a 2.5 percent stake in Olympus, has proposed investing some $640 million in cash-strapped Olympus.

But Olympus has also attracted other bidders including Sony Corp (6758.T) and Fujifilm Holdings (4901.T).

Kimoto told Bloomberg that at issue in Brazil is the way that the company handled doctors expenses for travel, meals or entertainment. He was also quoted as saying that the enquiries into Olympus' U.S. marketing operations may be part of a wider industry probe.

Shares in Olympus have shed nearly 40 percent since last October, when the company's former CEO Michael Woodford blew the whistle on a decade-long accounting fraud at the firm.

Terumo's lawsuit is the first made by an institutional shareholder against the scandal-tainted firm, which admitted last year it used improper accounting to conceal huge investment losses under a scheme that began in the 1990s.

Terumo said it would sue Olympus under Japan's Financial Instruments and Exchange Act for failing to disclose its accounting fraud before signing a business and capital tie-up with the medical equipment firm seven years ago.

Olympus allocated a little over 6 million shares to Terumo through a third-party allotment in August, 2005.

(Reporting by Junko Fujita and Dominic Lau; Editing by Michael Watson and Edwina Gibbs)

Related Quotes and News

Company

Price

Related News

  • Tweet this
  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

Comments (0)

This discussion is now closed. We welcome comments on our articles for a limited period after their publication.


You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: Panasonic rises 7 percent after strong quarterly results

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Panasonic rises 7 percent after strong quarterly results
Aug 1st 2012, 00:34

TOKYO | Tue Jul 31, 2012 8:34pm EDT

TOKYO (Reuters) - Shares of Panasonic Corp (6752.T) surged 7.1 percent to a three-week high of 585 yen on Wednesday after the electronics maker posted a near seven-fold increase in quarterly operating profit.

The company also set its sights on further business restructuring to revive the company.

Goldman Sachs lifted its 12-month price target on Panasonic to 690 yen from 670 yen and reiterated its "Buy" rating.

"Panasonic said it offset a profit hit of around 25 billion yen from weaker sales with more rationalization and more personnel and other fixed cost reductions, which enabled it to exceed profit guidance," Goldman Sachs said in a note to clients.

"We expect these positives to continue to have an effect from the second quarter, which should help absorb the impact of any further decline in sales. We raise our operating profit estimates by 4-8 percent to reflect internal efforts."

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: U.S. Steel profit beats Street view, stock soars

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
U.S. Steel profit beats Street view, stock soars
Jul 31st 2012, 21:47

By Steve James

Tue Jul 31, 2012 5:47pm EDT

(Reuters) - U.S. Steel Corp's (X.N) second-quarter profit beat Wall Street's expectations, sending its stock soaring, but the steelmaker also warned on Tuesday that third-quarter results would drop off because of global economic weakness and lower prices.

U.S. Steel's stock rose 9.1 percent to close at $20.65 on the New York Stock Exchange.

"We expect ... operating results to be positive in the third quarter but below our second-quarter results, reflecting the continued weakness in the North American, European and emerging market economies," Chief Executive Officer John Surma said in a statement.

He said average realized steel prices are expected to be lower in all three of U.S. Steel's businesses -- flat-rolled, European and tubular.

But later, he gave Wall Street analysts a positive message, saying flat-rolled steel and European prices were starting to move up again, even if they were still lower than a year ago.

"We see the market moving up in front of us," Surma said on a conference call. "It's still early in the process (and) we like to discuss things with the customers before we talk about it too much here, but the direction is pretty clear. It's up."

He said U.S. Steel was already booking orders into September, but he remained concerned about cheap foreign imports affecting domestic pricing.

"(But) The weaker euro (vs the U.S. dollar) should continue to discourage imports in the near-term," Surma said.

The U.S. Steel chief said the global economic recovery continues to be slow but there were some bright spots, such as the automotive segment, which he said is operating at levels well above last year.

Analyst David Gagliano of Barclays Capital Inc was bullish, saying he was not surprised that U.S. Steel expects third-quarter results to be weaker than the second quarter due to continued weakness in North America, Europe and emerging markets.

"The combination of another call for a trough in spot steel prices, resilient tubular segment expectations for the third quarter, the better-than-expected second-quarter results, and recent indications of recovering scrap steel prices, each bodes well for a near-term recovery in U.S. Steel shares," he said.

RIVALS STRUGGLE

U.S. Steel's earnings follow a string of poor second-quarter results from U.S. steelmakers struggling with weak demand. Nucor's (NUE.N) profit fell almost two-thirds and it forecast a drop in third-quarter earnings because increasing imports of cheaper foreign steel are pressuring already weak prices.

Steel Dynamics (STLD.O) reported a drop of more than 50 percent in profit and AK Steel (AKS.N) posted a second-quarter loss as sales fell 14 percent.

U.S. Steel said its second-quarter net profit dropped more than 50 percent to $101 million, or 62 cents per share, from $222 million, or $1.33 per share, a year earlier.

Excluding an $11 million after-tax early redemption premium on $300 million in senior notes due in 2013, earnings were 69 cents per share. On that basis, they beat analysts' estimates of 47 cents per share, according to Thomson Reuters I/B/E/S.

Revenue fell slightly to $5.0 billion from $5.1 billion, buoyed by a boom in the North American oil and gas industry.

The Pittsburgh-based company said total steel shipments declined in the second quarter to 5.43 million tons, from 5.5 million tons a year earlier, with prices falling in both the flat-rolled and European segments.

But revenue was boosted by higher prices for tubular steel, which is used for pipes in the oil and gas industry. However, the company noted that tubular shipments of 493,000 tons were 7 percent lower than in the first quarter.

"The results were better than many people expected but should have been better, given their favorable raw material position," said analyst Charles Bradford, of Bradford Research in New York.

He noted U.S. Steel has mines in Minnesota to produce its own iron ore, a key ingredient in steelmaking. "Despite having a substantial raw material cost advantage, U.S. Steel may lose money in its third quarter if its flat rolled segment breaks even, as they forecast," he said, citing substantial pension costs and interest expense.

The company said it expected break-even results for its flat-rolled segment in the third quarter due to lower average realized prices.

It forecast Slovakia-based European segment results to remain positive but lower than the second quarter, reflecting the continued economic challenges in that market.

For its tubular business, U.S. Steel forecast third-quarter results in line with the second quarter, with shipments expected to be lower as end-users adjust their drilling schedules.

(Reporting by Steve James; Editing by Gerald E. McCormick, Lisa Von Ahn, Dale Hudson and Jan Paschal)

  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: Array pain drug fails to better existing treatment, shares fall

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Array pain drug fails to better existing treatment, shares fall
Jul 31st 2012, 20:52

Tue Jul 31, 2012 4:52pm EDT

(Reuters) - Array BioPharma Inc (ARRY.O) said its experimental pain drug did not reduce pain better than the existing standard of care in a mid-stage study, sending its shares down 13 percent in after-market trade.

The compound, ARRY-797, reduced pain similar to the standard of care for chronic pain, Oxycodone ER. Patients taking Oxycodone showed a higher rate of adverse events in the trial.

The mid-stage study showed that ARRY-797 reduced pain significantly higher than a dummy drug -- the main goal.

Data from the trial suggests that ARRY-797 could be effective in treating both acute and chronic pain indications, the company said in a statement.

ARRY-797 is currently being tested in multiple ascending dose trials, the drugmaker added.

Shares of the Boulder, Colorado-based company, which have risen about 45 percent in the last three months, fell 13 percent to $4.50 in extended trade. They closed at $5.14 on Tuesday on the Nasdaq.

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: Coach hurt by soft sales in North America; shares slump

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Coach hurt by soft sales in North America; shares slump
Jul 31st 2012, 17:04

By Phil Wahba

Tue Jul 31, 2012 1:04pm EDT

(Reuters) - Upscale leather goods maker Coach Inc (COH.N) posted a marked slowdown in sales growth following a poorly timed decision to eliminate coupons at its outlet stores as the economy weakened and consumers pulled back.

The results drove Coach shares down more than 17 percent to $50.04, their worst single-day performance since just after the Sept 11, 2001, attacks on the World Trade Center and the Pentagon.

Sales at North American stores open at least a year rose 1.7 percent during the quarter that ended June 30, well below what Wall Street was expecting and the pace of preceding quarters.

Coach, popular for its high-quality but relatively affordable handbags and wallets, also faced competition from rivals like Fifth & Pacific Cos Inc's (FNP.N) kate spade stores and Michael Kors Holdings Ltd (KORS.N).

Coach's results were the latest sign that mid-tier consumers were becoming more cautious on how they spend, leaving companies to face grave consequences for any strategic missteps.

Spending by American consumers fell in June for the first time in nearly a year, when accounting for inflation, the Commerce Department said on Tuesday.

"You are worried about the core middle-income U.S. consumer," said Brian Sozzi, chief equities analyst at NBG Productions.

Coach said it expects North American same-store sales to be up by a low- to middle-single-digit percentage, compared with a 6.6 percent jump last year.

Coach had thought that it had the pricing power to cut back on coupons, but demand from consumers for discounts "is insatiable and growing," Chief Executive Lew Frankfort told analysts on a conference call.

Under pressure during the quarter from rivals, Coach backtracked in June on its plan to eliminate coupons at its factory outlet stores, which by some estimates are twice as big a business as its full-service stores. A Coach executive said same-store sales at outlets improved very quickly after the return of coupons.

Shoppers have shown before that they will balk when stores stop giving them deals - sales at mid-tier department store J.C. Penney Co Inc (JCP.N) plummeted after it stopped offering coupons this winter.

Companies as diverse as Starbucks Corp (SBUX.O), Chipotle (CMG.N) and Tiffany & Co (TIF.N) have all warned in recent weeks that the U.S. consumer is under stress.

The economy so far has not taken the same toll on all of Coach's competitors. Michael Kors forecast in June that same-store sales would rise 35 percent in the current quarter, while kate spade same-store sales rose 34 percent in the latest quarter.

Michael Kors "is very clearly aiming to build assets nearby Coach's full price and factory outlet stores to attack Coach's dominant market share," UBS analyst Michael Binetti wrote in a note.

CHINA, MEN TO PROVIDE BOOST

Coach said overall revenue in its fiscal fourth quarter that ended June 30 rose 12 percent to $1.16 billion, below the $1.2 billion that Wall Street analysts were expecting, according to Thomson Reuters I/B/E/S.

Net income was $251.4 million, or 86 cents per share, compared with $202.5 million, or 68 cents, a year earlier. That was a penny above what analysts were expecting.

Coach's sales at U.S. department stores such as Macy's Inc (M.N) and Nordstrom Inc (JWN.N), which account for 6 percent of company sales, were hurt by a drop in shipments.

The company continued to benefit from its overseas business. Same-store sales in China, where it is expanding quickly, rose by a double-digit percentage. Sales in Japan, its second-largest market, rose 16 percent, excluding the impact of currency.

It expects sales in China to hit $400 million this fiscal year, compared with $300 million last year. The company also said it expects its men's business to contribute one-quarter of its growth in the coming years.

Investments in store expansion, its men's business and ramped-up marketing will weigh on operating profits this year, the company said.

Frankfort warned of "the impact of the muted consumer environment in North America and a softening global macroeconomic outlook" for the new fiscal year, even as the company says its goal of double-digit percentage gains in sales and profit remains unchanged.

(Reporting by Phil Wahba in New York; Editing by Maureen Bavdek, John Wallace and Jan Paschal)

  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: Facebook stock slides to a record low, share-deluge looms

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Facebook stock slides to a record low, share-deluge looms
Jul 31st 2012, 17:17

  • Tweet
  • Share this
  • Email
  • Print
The Facebook logo is seen on a screen inside at the Nasdaq Marketsite in New York May 18, 2012. REUTERS/Shannon Stapleton

The Facebook logo is seen on a screen inside at the Nasdaq Marketsite in New York May 18, 2012.

Credit: Reuters/Shannon Stapleton

By Gerry Shih

SAN FRANCISCO | Tue Jul 31, 2012 1:17pm EDT

SAN FRANCISCO (Reuters) - Facebook Inc's shares dived 6 percent to another record low on Tuesday, sliding for the third straight day since a lackluster quarterly report showed decelerating user growth.

Investors have punished the stock of the No. 1 social network and other consumer-focused Internet companies such as Zynga Inc, questioning their ability to sustain growth and maintain lofty valuations. Last week, Facebook reported results but offered no outlook or forecast for the year, spooking investors who sought reassurance about growth in 2012.

Wall Street is also bracing for a potential deluge of millions of shares after August 16, when a post-IPO lockup period on employee share sales expires.

Despite having shed 40 percent of its value since a May 18 IPO, Facebook still trades at about 47 times forward earnings, versus Google Inc's 15 times.

On Tuesday, Bernstein Research analyst Carlos Kirjner upgraded Facebook to market perform, but estimated the lockup's expiry could unleash up to 211 million shares.

He valued Facebook's core display business at just $19 a share. But he said the company's potential around its innovative social graph was worth a $4 premium. Bernstein set Facebook's 12-month target price at $23.

The size of the current float could be nearly tripled by November, as more and more employees begin to sell, Kirjner warned.

Facebook stock was off 5.8 percent at $21.81 in afternoon trade.

(Reporting By Gerry Shih; Editing by Alden Bentley)

Related Quotes and News

Company

Price

Related News

  • Tweet this
  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/

Comments (1)

Let's delete all social media and re-embrace what's left of "real time."

Jul 31, 2012 1:43pm EDT  --  Report as abuse

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: Seagate shares tumble as slowing PC sales hit outlook

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Seagate shares tumble as slowing PC sales hit outlook
Jul 31st 2012, 14:38

Tue Jul 31, 2012 10:38am EDT

(Reuters) - Seagate Technology Plc's (STX.O) shares fell as much as 8 percent on Tuesday, after the hard disk drive (HDD) maker projected first-quarter revenue below estimates on slowing sales of personal computers.

The company has been hit by slowing economic growth and shaky sales of PCs as consumers shift toward tablets and smartphones.

FBN Securities cut its price target on Seagate's stock to $32, saying selling prices had started to decline from their peak levels after the Thailand floods last year and inventory had started rising.

Seagate's weak outlook follows an upbeat fiscal 2013 forecast from rival Western Digital Corp (WDC.O), which is banking on strong sales to big businesses.

The company forecast first-quarter sales of about $4 billion, below analysts' estimates of $4.62 billion, according to Thomson Reuters I/B/E/S.

"Our checks continue to show caution from PC vendors while the industry is still going through major product transitions," Barclays Capital analyst Ben Reitzes said.

Reitzes, however, raised his price target on Seagate's stock, saying the company represents a good investment in the longer term as it has raised its dividend and has said it will buy back shares.

Shares of the company fell 8 percent to $27.90 in early trading on the Nasdaq on Tuesday. The stock has dropped 7 percent since touching a life high of $32.55 on May 1.

(Reporting by Siddharth Cavale in Bangalore; Editing by Viraj Nair)

  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: Kulicke & Soffa results top estimates; sees upbeat fourth-quarter

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Kulicke & Soffa results top estimates; sees upbeat fourth-quarter
Jul 31st 2012, 12:01

Tue Jul 31, 2012 8:01am EDT

(Reuters) - Semiconductor equipment maker Kulicke & Soffa Industries Inc (KLIC.O) reported strong third-quarter results and forecast fourth-quarter revenue above estimates, driven by higher demand from chip foundries.

Shares of the company were up 12 percent at $11 in trading before the bell on Tuesday. The stock closed at $9.83 on the Nasdaq on Monday.

The company, which makes semiconductor back-end equipment such as ball and wedge bonders used for assembling chips, expects fourth-quarter revenue to be between $250 million and $270 million.

Analysts were expecting revenue of $190.4 million, according to Thomson Reuters I/B/E/S.

Net income for the third-quarter fell to $68.2 million, or 90 cents per share, from $70.7 million, or 95 cents per share.

The company, which counts world's biggest contract chip maker Taiwan Semiconductor Manufacturing Co Ltd (2330.TW) (TSM.N) as its customer, said revenue fell 13 percent to $255.5 million.

Analysts had expected earnings of 67 cents per share, excluding items, on revenue of $239.6 million.

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: Valero posts higher profit; to split off retail arm

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Valero posts higher profit; to split off retail arm
Jul 31st 2012, 12:23

Tue Jul 31, 2012 8:23am EDT

(Reuters) - U.S. refining company Valero Corp (VLO.N) posted a higher quarterly profit and said it would split off its retail business, lifting its shares nearly 7 percent in premarket trading on Tuesday.

"As independent companies, both retail and the remaining business will be better positioned to focus on their industry-specific strategies," Chairman and CEO Bill Klesse said in a statement.

The San Antonio company reported a second-quarter profit of $831 million or $1.50 per share, compared with $745 million, or $1.30 per share, a year earlier.

Valero said its retail arm reported record-high quarterly operating income of $172 million, up from $135 million a year earlier.

The company also raised its quarterly dividend by 17 percent to 17.5 cents per share.

Shares in Valero rose 6.9 percent to $27.89 in premarket trading.

(Reporting By Anna Driver in Houston and Matt Daily in New York; Editing by Gerald E. McCormick and Jo9hn Wallace)

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Monday, July 30, 2012

Reuters: Global Markets: Samsung Electronics shares jump more than 4 percent, hit two-and-a-half-month highs

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Samsung Electronics shares jump more than 4 percent, hit two-and-a-half-month highs
Jul 31st 2012, 05:33

SEOUL | Tue Jul 31, 2012 1:33am EDT

SEOUL (Reuters) - Shares in Samsung Electronics (005930.KS), the world's top technology firm by revenue, jumped more than 4 percent on Tuesday afternoon, along with the wider market's .KS11 gain, on buying by foreign investors, hitting their highest levels in about two-and-a-half months.

Samsung, which reported a record quarterly profit on Friday, was poised for its fourth consecutive day of stock-market gains.

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: Rongsheng shares tumble after U.S. insider trading probe

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Rongsheng shares tumble after U.S. insider trading probe
Jul 31st 2012, 01:26

Labourers work at a Rongsheng Heavy Industries shipyard in Nantong, Jiangsu province May 21, 2012. REUTERS/Aly Song

Labourers work at a Rongsheng Heavy Industries shipyard in Nantong, Jiangsu province May 21, 2012.

Credit: Reuters/Aly Song

HONG KONG | Mon Jul 30, 2012 9:26pm EDT

HONG KONG (Reuters) - Shares in China Rongsheng Heavy Industries Group Holdings Ltd (1101.HK) tumbled 18 percent on Monday after the U.S. securities regulator accused a company controlled by the shipbuilder's chairman of insider trading ahead of China's CNOOC Ltd's (0883.HK) bid for Canadian oil company Nexen Inc (NXY.TO).

The U.S. Securities and Exchange Commission filed a complaint in a U.S. court on Friday against a company controlled by Rongsheng Chairman Zhang Zhirong, and other traders, accusing them of making more than $13 million from insider trading ahead of CNOOC's $15.1 billion bid for Nexen.

On Monday, Rongsheng shares dropped as much as 18 percent to HK$1.15, a record low, leaving the company with a market capitalization of just over $1 billion. The company also issued a profit warning, saying first-half earnings would fall sharply as a result of a global shipbuilding downturn, a factor that has already pushed its shares down more than 75 percent in the past year.

"Since weak earnings had been expected and the stock had already come down quite a bit, the early selling was mainly triggered by the insider trading probe," said Steven Leung, a director at UOB Kay Hian.

"Investors are very sensitive to this kind of news and they simply unloaded their stakes on the worry that they will not be able to exit their investment if the company involved gets suspended," he said.

A June 2012 filing showed that billionaire Zhang held 47.75 percent of shares in Rongsheng.

Rongsheng - which entered a strategic cooperation agreement with CNOOC in 2010 - said in a Hong Kong filing that it did not expect the U.S. investigation to affect its operations. It said Zhang did not have an executive role in the company.

The SEC does not allege any wrongdoing by Zhang, but notes that he is the controlling shareholder of a company that engages in significant business activities with CNOOC. CNOOC in Beijing has declined comment on the matter.

"The news around the chairman comes on the back of other operational and credibility issues," Barclays said in a note to clients. "We think China Rongsheng presents significant company-specific risk."

The SEC said on Friday that a federal court in Manhattan had frozen assets worth more than $38 million belonging to Hong Kong-based Well Advantage, controlled by Zhang, and other unnamed traders who used accounts in Hong Kong and Singapore to trade in Nexen stock.

They made trading profits of $7 million and $6 million respectively using inside knowledge of the merger to buy Nexen shares before the announcement, the SEC alleges.

Zhang was ranked the 22th richest Chinese person by Forbes Magazine in September 2011. But his net worth fell by more than half in the past year to $2.6 billion in March 2012 as shares of Rongsheng tumbled.

Shares of Glorious Property Holdings Ltd (0845.HK), a Chinese real-estate developer in which Zhang has a 68 percent stake based on a December 2011 filing, also fell sharply. The stock fell as low as HK$1.12, down 15 percent from Friday.

Glorious Property said in a statement on Monday that the U.S. investigation would not affect the business of the developer. At HK$1.12, the shares are down 40 percent from its 2012 high late in February, leaving it with a market capitalization of about $1.13 billion.

CNOOC said on July 23 it had agreed to acquire Nexen for $15.1 billion, China's biggest foreign takeover bid. Shares of Nexen jumped almost 52 percent that day.

The unnamed Singapore traders used accounts in the names of Phillip Securities and Citibank C.N, while Well Advantage made its trades through accounts held at UBS Securities and Citigroup Global Markets. Neither of the Well Advantage accounts had traded Nexen shares since January 2012, and the Citigroup account had been completely dormant for over six months, the SEC says.

(Reporting by Charlie Zhu and Donny Kwok Additional reporting by Alison Leung; Editing by Neil Fullick)

  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: Vertex lowers Incivek view; new drug data lifts shares

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Vertex lowers Incivek view; new drug data lifts shares
Jul 30th 2012, 22:19

By Bill Berkrot

Mon Jul 30, 2012 6:19pm EDT

(Reuters) - Vertex Pharmaceuticals Inc (VRTX.O) reported further declines in sales of its hepatitis C drug Incivek and lowered its full year forecast for the medicine, but promising data on another drug for the virus lifted its shares more than 5 percent.

Vertex reported on Monday positive results from a very small, early stage trial of a hepatitis C medicine licensed from Alios BioPharma called ALS-2200 that appeared to allow investors to ignore falling Incivek sales. The experimental drug belongs to a class of medicines called nucleotide analogues, or nucs.

"It's all due to the data on their nuc," Brean Murray, Carret & Co analyst Brian Skorney said of the Vertex share jump.

He said the data looked comparable to early data from closely watched drugs being developed by Gilead Sciences Inc (GILD.O) and by Bristol-Myers Squibb Co (BMY.N).

"It puts them back in the hep C race," Skorney said. "It makes them a real player again."

If all goes well, Vertex said it could potentially begin pivotal Phase III testing of combinations including ALS-2200 by the end of 2013.

Second-quarter Incivek sales of $328 million fell short of Wall Street estimates of about $360 million and first-quarter sales of $356.9 million.

The company said it now expects full-year Incivek sales of $1.1 billion to $1.25 billion, down from its prior forecast of $1.5 billion to $1.7 billion.

Incivek, which was approved in May 2011, earlier this year eclipsed $1 billion in total sales, making it the fastest prescription drug to reach that mark in pharmaceutical history. But it must be taken with the difficult to tolerate injectable drug interferon and Incivek's life as a blockbuster is likely to end once all-oral treatment options become available over the next two years.

The continued decline in sales could indicate that patients are already beginning to wait for interferon-free regimens with fewer side effects being developed by several companies, including Vertex.

The company said it was still getting 70-75 percent of new hepatitis C prescriptions, but the number of patients beginning treatment has declined from initial demand. In addition to some patients delaying treatment, Vertex said many potential new patients were being recruited into clinical trials of new medicines being pursued by many companies.

"We believe ALS-2200 could become an important part of all-oral treatment regimens," Chief Executive Jeffrey Leiden told analysts on a conference call.

He said the company would move quickly to advance ALS-2200 into Phase II testing, and to develop all-oral regimens that include ALS-2200 in combination with its own medicines or those being developed by rival drugmakers.

Sales of the new cystic fibrosis drug Kalydeco were $46 million for the quarter, topping Wall Street estimates of about $41 million. Kalydeco, the first drug to treat the underlying cause of the life-shortening lung disease rather than just symptoms, won U.S. approval in late January and European approval just last week.

Kalydeco treats about 4 percent of cystic fibrosis patients with a specific gene mutation. It is currently testing Kalydeco in combination with another experimental drug with the hope of eventually addressing the larger cystic fibrosis population.

Vertex posted a net loss of $65 million, or 31 cents per share, after taking a $78 million charge as reserve against potential for excess Incivek inventory. That compared with a loss of $174 million, or 85 cents per share, a year ago.

Total revenue for the quarter of $418.3 million included $28 million in royalty payments from Johnson & Johnson (JNJ.N), which holds overseas rights to Incivek. That was short of analysts' revenue estimates of $471.2 million.

Vertex shares, which were already up about 50 percent this year, rose 5.3 percent to $52.60 in extended trading from their Nasdaq close at $49.96.

(Reporting by Bill Berkrot in New York; Editing by Bernard Orr, Leslie Gevirtz and Tim Dobbyn)

  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: Well-timed bullish options bet in Shaw Group raises eyebrows

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Well-timed bullish options bet in Shaw Group raises eyebrows
Jul 30th 2012, 16:54

By Angela Moon

NEW YORK | Mon Jul 30, 2012 12:54pm EDT

NEW YORK (Reuters) - With Shaw Group Inc (SHAW.N) shares up more than 50 percent on Monday, one investor made a stunning return by placing some well-timed bullish bets in options last week, raising eyebrows among options market watchers.

According to several options market participants, one investor purchased 2,000 Aug $29 calls in Shaw Group for 25 cents a piece on Thursday. With Shaw shares hitting all-time high near $44 on Monday, the calls were worth about $14, a stunning 5,600 percent return for the investor.

"The timing of this does look rather suspicious and the fact someone bought some out-of-the-money calls at the Aug 29-strike, which is 12 percent out-of-the-money, only adds to the suspicion," said Ryan Detrick, senior analyst at Schaeffer's Investment Research in Cincinnati, Ohio.

Chicago Bridge & Iron Co (CBI.N) said on Monday that it would buy Shaw Group for about $3 billion in cash and stock to create a big engineering and construction company focused on the energy industry. Netherlands-based CB&I offered $46 per share - $41 in cash and $5 in stock - a premium of 72 percent to Shaw's closing price on Friday, the companies said.

Shaw Group stock jumped about 60 percent to $43.70, while CB&I fell 14.9 percent to $34.67.

"Insider trading? Maybe. Certainly very shrewd timing on the purchase, wouldn't you say?" said Jon Najarian, co-founder of OptionMonster.com.

Suspicious trades prior to merger announcements are not uncommon in the options market. Just last week, a number of large well-timed bullish bets in the options of Canadian oil producer Nexen Inc (NXY.N) (NXY.TO) were spotted, ahead of a takeover deal announcement.

The U.S. Securities and Exchange Commission has now accused a Hong Kong-based firm of insider trading ahead of the public disclosure that China's oil producer CNOOC (0883.HK) plans to acquire Nexen.

(Reporting by Angela Moon; Editing by Leslie Gevirtz)

  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: Shares of Salix, Progenics drop after FDA rejects drug

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
Shares of Salix, Progenics drop after FDA rejects drug
Jul 30th 2012, 15:14

Mon Jul 30, 2012 11:14am EDT

(Reuters) - Shares of Salix Pharmaceuticals Ltd (SLXP.O) and Progenics Pharmaceuticals (PGNX.O) tumbled after U.S. health regulators declined to approve wider use of their drug for opioid-induced constipation and asked for more data.

Salix shares fell 12 percent to $46, while Progenics shares nearly halved in value to $5.84 on Monday morning on the Nasdaq.

The subcutaneous injection, Relistor, is already approved to treat opioid-induced constipation in patients with advanced illnesses where laxatives are not sufficient.

The companies were trying to get the injection approved for treating opioid-induced constipation in adult patients with chronic, non-cancer pain.

Cantor Fitzgerald analyst Irina Rivkind downgraded the stock to "hold" from "buy," and said the issues raised by the FDA could be related to the safety or effects of the drug class.

Morrisville, North Carolina-based Salix is also trying to get an oral version of the drug approved.

"We believe that the FDA's concerns on the subcutaneous form could also taint oral Relistor," Rivkind added.

Rivkind cut the peak sales estimate on Relistor for 2020 to $90 million from $300 million.

Credit Suisse analyst Michael Faerm also cut his price target on the stock by $3 to $50.

"Our price target is lowered to $50 based on our scenario of the subcutaneous and oral forms being delayed a year, with the approval probability for the subcutaneous (form) lowered to 25 percent," Faerm added.

Salix bought the rights to Relistor from Progenics in April 2011, just two months after Progenics' former partner Pfizer (PFE.N) returned rights to the drug.

According to the deal with Salix, Progenics would have received $40 million in milestone payments had the FDA approved the drug for the wider indication.

(Reporting by Esha Dey and Prateek Kumar in Bangalore; Editing by Viraj Nair, Roshni Menon)

  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

Reuters: Global Markets: CB&I to buy Shaw Group for $3 billion

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com
CB&I to buy Shaw Group for $3 billion
Jul 30th 2012, 12:49

Mon Jul 30, 2012 8:49am EDT

(Reuters) - Chicago Bridge & Iron Co (CBI.N) said on Monday that it would buy Shaw Group Inc (SHAW.N) for about $3 billion in cash and stock to create a big engineering and construction company focused on the energy industry.

Netherlands-based CB&I offered $46 per share - $41 in cash and $5 in stock - a premium of 72 percent to Shaw's closing price on Friday, the companies said.

Shaw stock jumped 65 percent to $44.05 in premarket trading, while CB&I fell 8.5 percent to $37.25.

Shares of other engineering stocks also rose. Fluor Corp (FLR.N) gained 4.4 percent, and Foster Wheeler AG (FWLT.O) was up 7.3 percent.

Baton Rouge, Louisiana-based Shaw provides engineering, construction and maintenance services to oil companies, manufacturers, and utilities. It recorded 2011 sales of $5.9 billion and employs about 27,000 people.

CB&I, whose clients include energy companies like Chevron Corp (CVX.N) and Exxon Mobil Corp (XOM.N), said it would use cash on the balance sheets of both companies, along with about $1.9 billion in debt, to finance the acquisition.

The deal will add to earnings in the first year, CB&I said, adding that it plans to expand in areas such as nuclear, gas and coal power generation.

Shaw will continue as a business segment branded as CB&I Shaw. Shaw Chief Executive Officer J.M. Bernhard Jr. will leave after the deal closes in early 2013, and CB&I CEO Philip Asherman will lead the combined company.

Bank of America Merrill Lynch (BAC.N) is the financial advisor to CB&I. Morgan Stanley & Co LLC (MS.N) is Shaw`s exclusive financial advisor.

(Reporting by A. Ananthalakshmi in Bangalore and Nick Zieminski in New York; Editing by Gerald E. McCormick and Lisa Von Ahn)

  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions
Read more »

 
Great HTML Templates from easytemplates.com.